Yutaro Kasai
Founder and CEO @ Angel Bridge
Yutaro Kasai is a Series A investor at Angel Bridge focused on Information Technology and Software. Yutaro Kasai is the Founder and CEO at Angel Bridge. Yutaro Kasai attended The University of Chicago Booth School of Business.
- Total investments:
- 23
- Last investment:
- Lead investor:
- 30%
Last updated:
For AI agents: llms.txt
Industries Yutaro Kasai invests in
Stages Yutaro Kasai invests in
Countries Yutaro Kasai invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Information Technology 7 (30%)
- Software 6 (26%)
- Financial Services 4 (17%)
- Finance 3 (13%)
- Biotechnology 3 (13%)
Stage
- Series A 11 (48%)
- Seed 5 (22%)
- Series B 3 (13%)
- Funding Round 2 (9%)
- Venture - Series Unknown 2 (9%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| PeopleX encourages and assists employees in their professional development. | $34M / Series A / Sep 02, 2026 | ||
| Fivot is a financial company that provides venture capital, financing, credit, money lending, and prepaid payment services. | $6.5M / Series B / Nov 05, 2025 | ||
| SoftRoid provides a software robot that patrols and collects data for analyzing the construction site. | $10M / Series A / Sep 25, 2025 | ||
| Mechano Cross is a mechanical company that offers mechanochemical organic synthesis technology for solution reactions. | Seed / Sep 05, 2025 | ||
| Fermelanta produces rare plant-based ingredients through microbial fermentation. It engineers a cell to build a biosynthetic pathway of target molecules with gene transfer and disruption. | $13.6M / Series A / Aug 29, 2025 | ||
| Goals specializes in development, sales and operational support for cloud services for food service companies. | $9M / Series B / Aug 06, 2025 | ||
| Logomix Inc is a mammalian cellular genome architect startup. Logomix proprietary platform, Geno-Writing™, technology integrates large-scale (Mb) human genome-writing technologies and providing genetically architected versatile human cells and/or downsized cells and microbes for drug development and cell & gene therapy area.Majority ofthe cell engineering companies are currently focused on optimization of gene clusters by automatic high throughput system however, Logomix’s Geno-Writing™ provides the required tools for dealing with mammalian or complex genomes. Logomix works with partners by providing new biology-based solutions to co-create business and social values on Geno-Writing™ platform Current Focus Area includes: 1. Human Health & Therapeutics 2. Biomaterials & Chemicals 3. Agriculture & EnvironmentLogomix has 11 ongoing collaborative research partnerships. Currently Logomix is specifically looking for industry partners to address unmet needs in neurodegenerative disease areas. | $18.8M / Jul 30, 2025 | ||
| Reborna Biosciences provides research and development in the field of genetic diseases. The company develops therapeutic options for area of unmet medical needs in genetic rare disease. The company's technology enables low-molecular compounds to target ribonucleic acid. The company provides new disease-modifying drugs for patients sufferingfrom rare genetic diseases including spinal muscular atrophy. | $5.3M / Jun 25, 2025 | ||
| Plainer is an IT company that provides software development, data management, and SaaS solutions. | $2.8M / Series A / May 20, 2025 | ||
| Emole is a platform that connects content creators with viewers through short drama content, offering a variety of engaging stories. | $5.7M / Series A / Mar 28, 2025 | ||
| See all 23 investments → | |||
Co-Investors
About Angel Bridge
Angel Bridge is a angel investor groups in Japan and provide high quality and abundant funds to excellent companies.
Angel Bridge Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Masayoshi Hayashi
Partner
|
|||
|
Yutaro Kasai
Founder and CEO
|
|||
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Yutaro Kasai invest in?
Yutaro Kasai invests primarily in Information Technology, Software and Financial Services startups, most often at Series A and Seed stage. Most of the 23 investments tracked by Shizune back companies in Japan. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Yutaro Kasai?
Public channels for Yutaro Kasai include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Yutaro Kasai last invest?
The most recent investment recorded for Yutaro Kasai closed in Sep 2026. Shizune tracks 23 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
